A new tool generates and labels customized aneuploid cells in living tissue to observe the behavior of these cells in ...

BMS will co-develop and co-commercialize BioNTech’s bispecific antibody BNT327 for solid tumors in a deal worth up to $11.1B ...

Insilico plans late-stage trials for rentosertib following positive mid-stage safety and efficacy data for idiopathic ...

Infuzide, a newly synthesized compound, shows potent activity against drug-resistant microbes, offering new hope in the fight against AMR.

The investigational drug demonstrated robust STAT6 degradation in blood and skin that was well tolerated and safe in healthy ...

Combination treatment could also benefit patients with lung, bowel, pancreatic and other solid cancers who don’t respond to ...

A new study found that aged neurons have defects in key proteins that make them vulnerable to molecular stress and neurodegenerative damage.

Sanofi to acquire Blueprint Medicines for up to $9.5B to expand its rare immunological disease portfolio, including an ...

Phase I trial patients experienced shrinkage of brain tumors and extended survival rates beyond the standard prognosis of one ...

Therapeutic plasma exchange combined with intravenous immunoglobulin reduced biological age on average by 2.6 years, as ...

A decades-old TB vaccine turned cancer therapy may unlock new immunotherapies by reprogramming immune cell development in the ...

Replacing PEG with PCB in lipid nanoparticles led to potent mRNA vaccines that avoided unwanted immune responses.